Cognition Therapeutics, Inc. provided consolidated earnings guidance for the year ended December 31, 2023. For the year, the company expected net loss to be approximately $25.6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.55 USD | -1.92% | +30.10% | +37.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.84% | 102M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023